■治疗药物监测(TDM)可以成为抗丙型肝炎病毒(抗HCV)药物临床管理的有用工具。生物样品中各类抗HCV药物的测定方法有,因此,需要临床实验室。
■在这项工作中,采用LC-MS/MS方法,我们旨在开发一种多重方法来鉴定以下抗HCV药物:利巴韦林(RBV),Boceprevir(BOC),Telaprevir(TVR),Simeprevir(SIM),Daclatasvir(DAC),液体血浆和干血浆点(DPS)中的索非布韦(SOF)及其代谢物GS331007(SOFM)。
■对液体血浆和DPS均采用单步萃取-脱蛋白。开发了反相液相色谱与MRM检测相结合的方法,用于多重药物检测和定量。
■灵敏度(以LOQ表示)为10(±1.2),10(±4.9),10(±4.4),10(±4.4),10(±6.4),10(±3.4),RBV为10(±6.4)ng/ml,SOFM,SOF,DAC,中行,TVR,还有SIM,所有药物的准确度(以BIAS%表示)均<10%;所有药物的可重复性(日内和日间CV%)均<10%;所有药物的动态范围为10-10,000ng/ml。
■小说,简单,成功开发了目前临床上各种抗HCV药物TDM的快速、稳健的LC-MS/MS多重检测方法。对DPS样品的应用使得TDM也可用于门诊患者。
UNASSIGNED: Therapeutic drug monitoring (TDM) can be a useful tool in the clinical management of anti-hepatitis C virus (anti-HCV) drugs. Methods for the determination of various types of anti-HCV drugs in biological samples are, therefore, needed for clinical laboratories.
UNASSIGNED: In this work, employing the LC-MS/MS approach, we aimed to develop a multiplexed method for identification of the following anti-HCV drugs: Ribavirin (RBV), Boceprevir (BOC), Telaprevir (TVR), Simeprevir (SIM), Daclatasvir (DAC), Sofosbuvir (SOF) and its metabolite GS 331007 (SOFM) in liquid plasma and in dried plasma spots (DPSs).
UNASSIGNED: A single-step extractive-deproteinization was employed for both liquid plasma and DPSs. Reverse-phase liquid chromatography coupled with MRM detection was developed for multiplexed drug detection and quantification.
UNASSIGNED: Sensitivities (expressed as LOQ) were 10 (±1.2), 10 (±4.9), 10 (±4.4), 10 (±4.4), 10 (±6.4), 10 (±3.4), 10 (±6.4) ng/ml for RBV, SOFM, SOF, DAC, BOC, TVR, and SIM, respectively; accuracy (expressed as BIAS%) was <10% for all drugs; reproducibility (intra- and inter-day CV%) was <10% for all drugs; dynamic range was 10-10,000 ng/ml for all drugs.
UNASSIGNED: A novel, simple, rapid and robust LC-MS/MS multiplex assay for the TDM of various anti-HCV drugs that are currently in the clinic was successfully developed. Application to DPS samples enabled TDM to be used for outpatients as well.